Back to Dashboard
RARE · Healthcare

Ultragenyx Pharmaceutical In

USA Healthcare Filing: 2026-06-30
20/100
Smart-money confidence
Bottom band — money moving out

1 member of Congress bought

Stocks scoring 0–25 beat the S&P 500 39.9% of the time over the next three months, since 2015. How we measured this →

5
hedge funds
hold it · 2 added, 3 trimmed
1
in Congress
traded it in the past year · 1 bought, 0 sold
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works Consensus buy — 2 of 3 sources positive →
Market cap
$1.6B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About ULTRAGENYX PHARMACEUTICAL IN

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with…

Who's behind the signal
Every informed buyer we can see on RARE, across all three feeds.
Hedge funds · 5
AQR Capital Management Increased +43%
D.E. Shaw & Co Increased +37%
Renaissance Technologies Decreased −26%
Citadel Advisors Decreased −90%
Congress · 2
Kurt Schrader bought
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 6 on record
Disclosures from 2021-08-30 to 2026-09-29
Trade date Member Chamber Action Amount
2026-09-29 Gilbert Ray Cisneros, Jr. · D-CA House Bought $1,001 - $15,000
2026-03-03 Gilbert Ray Cisneros, Jr. · D-CA House Bought $1,001 - $15,000
2026-02-18 Gilbert Ray Cisneros, Jr. · D-CA House Bought $1,001 - $15,000
2025-08-08 Gilbert Ray Cisneros, Jr. · D-CA House Bought $1,001 - $15,000
2025-07-15 Gilbert Ray Cisneros, Jr. · D-CA House Bought $1,001 - $15,000
2021-08-30 Kurt Schrader · D-OR House Bought $1,001 - $15,000
Not a model pick — but on our radar. ULTRAGENYX PHARMACEUTICAL IN isn't in the top-10 model right now, but 5 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
5
Investors
0
New positions
2
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to reset Pinch to zoom · drag sideways to move through time
A member of Congress bought A member sold
Return: High: Low:

Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.

Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Portfolio Allocation
How much of each investor's portfolio is allocated to ULTRAGENYX PHARMACEUTICAL IN
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ULTRAGENYX PHARMACEUTICAL IN or any security.

订阅每周更新

我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费,直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订 · 隐私